Researchers at the Japan Advanced Institute of Science and Technology have identified a gut bacterium, Ewingella americana, capable of eliminating colorectal cancer tumors in mice with a 100% success rate after a single intravenous dose. Published in the journal Gut Microbes, the study suggests that the microbiomes of lower vertebrates could provide a new frontier for developing targeted, high-efficacy cancer therapies.
How Ewingella americana Targets Tumors
The research team, led by Professor Eijiro Miyako, isolated 45 bacterial strains from the intestines of Japanese tree frogs, fire belly newts, and grass lizards. Through systematic screening, they found that nine of these strains possessed anti-tumor properties. Among them, Ewingella americana demonstrated the most significant therapeutic impact.
Unlike traditional treatments that often rely on indirect systemic effects, this bacteria works by directly attacking tumor sites. According to the study, the treatment not only destroys cancer cells but also triggers the host’s immune system to facilitate “comprehensive tumor destruction.” This dual-action approach helped the researchers achieve a complete response rate in mice models of colorectal cancer, outperforming standard therapies like liposomal doxorubicin and immune checkpoint inhibitors.
Did you know?
The researchers found that E. americana is cleared from the body rapidly, with a half-life of approximately 1.2 hours. It becomes completely undetectable in the blood within 24 hours, which contributes to its favorable safety profile.
Safety and Biological Impact
The Japan Advanced Institute of Science and Technology reported that E. americana showed no signs of colonization in vital organs, including the heart, liver, lungs, or kidneys. During a 60-day observation period, the mice exhibited no chronic toxicity, with only mild, transient inflammatory responses that resolved within 72 hours.
This safety profile stands in contrast to many conventional chemotherapy agents, which often cause widespread systemic damage. By utilizing naturally occurring microbes found in lower vertebrates, the team believes they have tapped into a “treasure trove” of biological resources that have not yet been characterized for human medical use.
Future Directions in Cancer Research
The success of the initial study has prompted plans to expand testing to other malignancies, including breast cancer, pancreatic cancer, and melanoma. The research team is currently investigating how to optimize delivery methods to maximize therapeutic impact. Potential strategies include dose fractionation—breaking the treatment into smaller, repeated doses—and intra-tumoral injection to concentrate the bacteria directly at the site of the malignancy.
Furthermore, the team plans to examine whether E. americana can act synergistically with existing immunotherapies. By combining this bacterial approach with established treatments, researchers hope to improve outcomes for patients who do not respond well to current standard-of-care protocols.
Frequently Asked Questions
Can this frog-derived bacteria be used for humans today?
No. The research is currently in the preclinical stage, meaning it has only been tested in mice. Extensive human clinical trials are required to determine if the treatment is safe and effective for people.
How does this differ from standard chemotherapy?
Standard chemotherapy often uses chemical agents that affect both cancerous and healthy cells. The E. americana approach uses live bacteria that are specifically screened for their ability to target tumors while avoiding colonization of healthy organs.
What other animals are being studied for cancer breakthroughs?
Scientists are exploring various biological sources for cancer research, including scorpion venom, which has shown promise in targeting breast cancer cells, and various vaccine technologies currently in development for melanoma.
Are you interested in the latest developments in medical biotechnology? Subscribe to our newsletter for updates on emerging cancer research and breakthroughs in microbial therapy.
Worth a look